The Clinicians Speak, page-142

"ConclusionBTM offers a safe and reliable reconstructive option in challenging wounds that would otherwise require more complex operations."

The indirect savings appear to be a theme in the case studies I've read. The bean counters ne
ed to consider the total risk profile and factor in potential costs as well as known costs. Indirect costs could include additional treatment, accommodation, patient time/suffering, admin etc.

As the word gets out I expect direct costs and performance to drive uptake. Hopefully the green shoots I am seeing in the reports regarding minimisation of costs due to further complications come to be part of the value proposition.

It's a likely winner in all respects IMO as compared to competitors. New gold standard coming up.

.....and in my experience accountants struggle with intangibles and the concept of risk weighted financial decisions.